AI is spitting out more potential drugs than ever. This startup wants to figure out which ones matter.

10x Science, a new startup, has secured $4.8 million in seed funding to address a critical bottleneck in drug development: characterizing the vast number of potential drug candidates generated by AI. While AI excels at predicting protein structures and identifying potential treatments, the practical step of analyzing and measuring these candidates for testing and production remains time-consuming and complex. The startup's platform combines deterministic algorithms with AI agents to interpret data from mass spectrometry, a key technique for understanding molecular structures. Founded by experienced biochemists and a computer scientist, 10x Science aims to make this complex analysis faster and more accessible, even for researchers without specialized equipment or extensive expertise. Early users report significant speed-ups and appreciate the AI's ability to explain its conclusions and adapt to different molecules. The company plans to use its funding to expand its engineering team, refine its model, and offer its SaaS platform to pharmaceutical companies and academic researchers, ultimately aiming to define a new form of "molecular intelligence" and become an essential tool in the drug development pipeline.

(Source：TechCrunch)